PPAR-y agonist

Current evidence suggests that PPAR activation may limit inflammation and hence atherosclerosis. Both PPAR-a and PPAR-y can reduce T-cell activation, as shown by decreased production of EFN-y. PPAR-a agonists also rqness endothelial VCAM-1 expression and inhibit the inflammatory activation of vascular SMCs, while PPAR-y agonists repress endothelial chemokine expression and decrease macrophage MMP production. 

Hypolipoproteinemia is likely to be a rare adverse effect. The measurement of HDL cholesterol and triglycerides before and after staring thiazolidinedione therapy will allow its detection. On withdrawing therapy concentrations return to normal. This effect may be specific to rosiglitazone, as it is becoming apparent that the PPAR-y agonists vary in their effects. 

PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR)y AGONISTS FOR DIABETES... 

T 22573 Troglitazone Antitumor agent PPAR-y agonist induces apoptosis via a p53 pathway. Microtube Inhibitors ... 

Spears M, Donnelly I, Jolly L, Brannigan M, Ito K, McSharry C, Lafferty J, Chaudhuri R, Braganza G, Bareille P, Sweeney L, Adcock IM, Bames PJ, Wood S, Thomson NC. Bronch-odilatory effects of the PPAR-y agonist rosiglitazone in smokers with asthma. Clin Pharmacol Ther 2009 86 49-53. 

The tubular abnormalities that tenofovir can cause may be due to down-regulation of a variety of ion transporters. Because rosiglitazone, a PPAR-y agonist induces the expression of many of these transporters, it has been successfully used to ameliorate tenofovir-induced nephrotoxicity in rats [122 ]. 

Thiazolidinedio-nes or PPAR-y agonists Rosiglitazone, pioglitazone Binding on the PPAR-y, it aetivates the transcription of speeifie genes of lipid metabolism Sensitivity to insulin, anti-inflammatory effects and amelioration of hypertension, microalbuminuria and hepatic steatosis Severe liver failure, death and increased cardiac risk... 

---